Skip to main content

Straumann plans to build innovation center in the Basel Area

| News

Straumann plans to build innovation center in the Basel Area

29.10.2021

The Basel-based dental specialist Straumann is planning to construct a new technology and innovation center in Arlesheim in the canton of Basel-Landschaft. This should lead to the creation of 240 new jobs. Moreover, Straumann has acquired a stake in the medtech startup Mininavident, which is also based in the Basel Area.

Straumann's headquarters in Basel (img: Straumann Group)

The dental implant supplier Straumann increased revenue by 31.6 percent to 496 million Swiss francs in the third quarter of the year, further details of which can be found in a press release. For the full year, organic revenue growth in the high-thirties percentage range is being targeted, while profitability should at least be on a par with the level recorded in 2019. At the same time, the Basel-based firm is implementing an investment program to ensure it remains fit for the future. As such, it has announced that it will be investing a total of 18 million Swiss francs on the construction of a new technology and innovation center, which is expected to be operational by the first half of 2023.

Straumann will “host research and development, global supply chain, logistics and warehousing activities” at this new center. “In addition, the Swiss sales affiliate and commercial laboratory will be located at the site”, Straumann explains in the press release. As the newspaper “bz” writes in an article that includes comments from CEO Guillaume Daniellot, Straumann intends to create 240 new jobs at the technology and innovation center. The Arlesheim location is intended to emphasize the importance of the Basel Area for the company. In addition to the new jobs, Straumann will also bring together expert groups from the region at the new center. The company’s headquarters will remain at the site adjacent to Basel SBB railway station, according to an article by telebasel.

Furthermore, Straumann has made another investment, on this occasion acquiring a 39 percent stake in Mininavident, as the medtech firm from Liestal in the canton of Basel-Landschaft writes in a press release. The spin-off from the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) and University Hospital Basel has developed a navigation system for dental implants in the form of the DENACAM. Users receive real-time support in 3D to help accurately position the implant. In addition to the equity participation, the two firms have also agreed a partnership for the further development and distribution of the system, which will see Straumann become the worldwide exclusive distribution partner. Mininavident is very proud of this investment and cooperation with one of the world’s leading dental implant companies, CEO Michael Breitenstein comments in the press release.

With decades of expertise in healthcare and mechanics, the Basel Area has become a sought-after location for medtech startups.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.